Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
65.67
-0.87 (-1.31%)
Dec 5, 2025, 4:00 PM EST - Market closed
Cytokinetics Revenue
Cytokinetics had revenue of $1.94M in the quarter ending September 30, 2025, with 318.14% growth. This brings the company's revenue in the last twelve months to $87.21M, up 2,609.26% year-over-year. In the year 2024, Cytokinetics had annual revenue of $18.47M with 145.34% growth.
Revenue (ttm)
$87.21M
Revenue Growth
+2,609.26%
P/S Ratio
89.62
Revenue / Employee
$175,122
Employees
498
Market Cap
8.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
| Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
| Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
| Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
| Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CYTK News
- 2 days ago - 3 Potential Mid-Cap Biotech Buyout Targets In 2026 - Seeking Alpha
- 17 days ago - Cytokinetics: A Heavily Mispriced Cardiovascular Platform - Seeking Alpha
- 17 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 19 days ago - Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - GlobeNewsWire
- 23 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Newsfile Corp
- 25 days ago - CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Newsfile Corp
- 26 days ago - Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 - GlobeNewsWire
- 4 weeks ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics - Newsfile Corp